Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
Article Details
- CitationCopy to clipboard
Zhang L, Nadzan AM, Heyman RA, Love DL, Mais DE, Croston G, Lamph WW, Boehm MF
Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.
J Med Chem. 1996 Jul 5;39(14):2659-63.
- PubMed ID
- 8709094 [ View in PubMed]
- Abstract
Retinoic acid receptor (RAR) active retinoids have proven therapeutically useful for treating certain cancers and dermatological diseases. Herein, we describe the discovery of two new RAR active trienoic acid retinoids, (2E,4E,6E)-7-(3,5-di-tert-butylphenyl)-3-methylocta-2, 4,6-trienoic acid (10a, ALRT1550) and (2E,4E,6Z)-7-(3,5-di-tert-butylphenyl)-3-methylocta-2, 4,6-trienoic acid (10b, LG100567). ALRT1550 is a RAR selective retinoid which exhibits exceptional potency in both competitive binding and cotransfection assays. Moreover, it is the most potent antiproliferative retinoid described to date and thus has implications for the treatment of certain cancers. LG100567 is a potent panagonist which activates both RARs and retinoid X receptors.
DrugBank Data that Cites this Article
- Binding Properties